{"disease":{"id":"cp","name":"cp"},"drugs":{"marketed":[{"drug_id":"asciminib","indication_name":"Newly diagnosed Ph+ CML in CP","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Scemblix","generic_name":"ASCIMINIB","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase ABL1","drug_class":"","quality_score":69,"revenue":"894","mechanism":"Scemblix works by blocking the ABL1 enzyme, which is involved in the growth and survival of cancer cells."},{"drug_id":"asciminib","indication_name":"Previously treated Ph+ CML in CP","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Scemblix","generic_name":"ASCIMINIB","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase ABL1","drug_class":"","quality_score":69,"revenue":"894","mechanism":"Scemblix works by blocking the ABL1 enzyme, which is involved in the growth and survival of cancer cells."},{"drug_id":"asciminib","indication_name":"Ph+ CML in CP with T315I mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Scemblix","generic_name":"ASCIMINIB","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase ABL1","drug_class":"","quality_score":69,"revenue":"894","mechanism":"Scemblix works by blocking the ABL1 enzyme, which is involved in the growth and survival of cancer cells."},{"drug_id":"ponatinib-hydrochloride","indication_name":"CP-CML with resistance or intolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PONATINIB HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"ABL, T315I mutant ABL, VEGFR, PDGFR, FGFR, EPH receptors, SRC family, KIT, RET, TIE2, FLT3","drug_class":"","quality_score":53,"revenue":null,"mechanism":"Ponatinib inhibits multiple kinases, including ABL and its T315I mutant, reducing tumor size in mice."},{"drug_id":"chembl-chembl941","indication_name":"Ph+ CML in BC, AP, CP","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IMATINIB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":12,"revenue":null,"mechanism":null},{"drug_id":"histrelin-acetate","indication_name":"Central Precocious Puberty (CPP)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"HISTRELIN ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":null},{"drug_id":"synarel","indication_name":"Treatment of central precocious puberty (CPP) (gonadotropin-dependent precocious puberty) in children of both sexes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Synarel","generic_name":"Nafarelin Acetate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Gonadotropin-releasing hormone receptors","drug_class":"Gonadotropin-releasing hormone agonists","quality_score":67,"revenue":null,"mechanism":"Gonadotropin-releasing hormone agonist medication"},{"drug_id":"pf-06823859","indication_name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy in patients who are not eligible for platinum-containing chemotherapy and have a PD-L1 combined positive score (CPS) ≥ 10 as determined by an FDA-approved test.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-06823859","indication_name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy in patients who are not eligible for platinum-containing chemotherapy and have a PD-L1 combined positive score (CPS) ≥ 10 as determined by an FDA-approved test in combination with axitinib.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-06823859","indication_name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy in patients who are not eligible for platinum-containing chemotherapy and have a PD-L1 combined positive score (CPS) ≥ 10 as determined by an FDA-approved test in combination with lenvatinib.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-06823859","indication_name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy in patients who are not eligible for platinum-containing chemotherapy and have a PD-L1 combined positive score (CPS) ≥ 10 as determined by an FDA-approved test in combination with pembrolizumab and lenvatinib.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-06823859","indication_name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy in patients who are not eligible for platinum-containing chemotherapy and have a PD-L1 combined positive score (CPS) ≥ 10 as determined by an FDA-approved test in combination with pembrolizumab and lenvatinib in patients with a PD-L1 CPS ≥ 10 as determined by an FDA-approved test.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"buphenyl","indication_name":"Deficiency of carbamylphosphate synthetase (CPS)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Buphenyl","company_name":"Amgen","drug_phase":"marketed","molecular_target":"Aldose reductase, Histone deacetylase 1, Histone deacetylase 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":13,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05211206","title":"IV Fluids and Post-ERCP Pancreatitis","phase":"","overall_status":"UNKNOWN","enrollment_count":13000,"lead_sponsor_name":"University of Calgary","has_results":false},{"nct_id":"NCT04189822","title":"Hearts in Rhythm Organization (HiRO)National Registry and Bio Bank","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":10000,"lead_sponsor_name":"University of British Columbia","has_results":false},{"nct_id":"NCT05219123","title":"Guidewire Management in ERCP","phase":"","overall_status":"COMPLETED","enrollment_count":7461,"lead_sponsor_name":"University of Calgary","has_results":false},{"nct_id":"NCT04323878","title":"Early CPAP in COVID-19 Patients With Respiratory Failure. A Prospective Cohort Study.","phase":"","overall_status":"COMPLETED","enrollment_count":6000,"lead_sponsor_name":"Mario Negri Institute for Pharmacological Research","has_results":false},{"nct_id":"NCT03013283","title":"CPAP and NIV Interfaces : Side-effects in Home Care Patients","phase":"","overall_status":"COMPLETED","enrollment_count":6000,"lead_sponsor_name":"University Hospital, Montpellier","has_results":false},{"nct_id":"NCT05929404","title":"Incidence and Predictors of Bleeding During and Following ERCP","phase":"","overall_status":"COMPLETED","enrollment_count":5872,"lead_sponsor_name":"University of Calgary","has_results":false},{"nct_id":"NCT07039955","title":"Effect of Daily Chlorhexidine Bathing and Antibiotic/PPI Stewardship on Prevention of CPE Transmission and Infection","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":5760,"lead_sponsor_name":"Chuncheon Sacred Heart Hospital","has_results":false},{"nct_id":"NCT04661332","title":"Registry of Endoscopic Retrograde Cholangiopancreatographies Performed in Humans","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"Istituto Clinico Humanitas","has_results":false},{"nct_id":"NCT06334510","title":"Evaluate the Safety and Efficacy of Quadrivalent Influenza in Real-world Situations.","phase":"","overall_status":"COMPLETED","enrollment_count":4900,"lead_sponsor_name":"Hualan Biological Bacterin Co. Ltd.","has_results":false},{"nct_id":"NCT07071441","title":"Indomethacin vs Diclofenac for Preventing PEP","phase":"NA","overall_status":"RECRUITING","enrollment_count":4050,"lead_sponsor_name":"Air Force Military Medical University, China","has_results":false},{"nct_id":"NCT07391787","title":"Low-acid Contrast Media for Preventing Post ERCP Pancreatitis","phase":"","overall_status":"COMPLETED","enrollment_count":3979,"lead_sponsor_name":"Shandong University","has_results":false},{"nct_id":"NCT05220774","title":"Conscious Sedation Versus Anesthesia for ERCP","phase":"","overall_status":"COMPLETED","enrollment_count":3174,"lead_sponsor_name":"University of Calgary","has_results":false},{"nct_id":"NCT07485101","title":"Glycemic Targets During CPB in Elderly Diabetes","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Beijing Anzhen Hospital","has_results":false},{"nct_id":"NCT04425993","title":"Rectal Indomethacin Versus Rectal Indomethacin and Sublingual Nitrate for PEP Prevention","phase":"NA","overall_status":"UNKNOWN","enrollment_count":2700,"lead_sponsor_name":"Air Force Military Medical University, China","has_results":false},{"nct_id":"NCT07329790","title":"Indian National Study to Assess Incidence and Severity of Post-ERCP Pancreatitis After Following SOP","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2366,"lead_sponsor_name":"Asian Institute of Gastroenterology, India","has_results":false},{"nct_id":"NCT03756116","title":"Effect of Papillary Epinephrine Spraying for the Prevention of Post-ERCP Pancreatitis in Patients Received Octreotide","phase":"NA","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"The Second Hospital of Nanjing Medical University","has_results":false},{"nct_id":"NCT05667987","title":"Evaluation of the Benefit of Lidocaine on the Prevention of the Risk of Post Endoscopic Retrograde Cholangio-pancreatography Pancreatitis.","phase":"NA","overall_status":"RECRUITING","enrollment_count":1800,"lead_sponsor_name":"GCS Ramsay Santé pour l'Enseignement et la Recherche","has_results":false},{"nct_id":"NCT05800626","title":"Prediction of PEP Based on the Appearance of the Major Duodenal Papilla","phase":"","overall_status":"UNKNOWN","enrollment_count":1740,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT03713879","title":"Comparative Effectiveness Between Indomethacin and Pancreatic Stenting in the Prevention of Post ERCP Pancreatitis","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1734,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT07088757","title":"Low-Dose vs Standard-Dose Indomethacin for Preventing Post-ERCP Pancreatitis","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":1366,"lead_sponsor_name":"Changhai Hospital","has_results":false},{"nct_id":"NCT06795971","title":"Effects of Face Mask Continuous Positive Airway Pressure Vs. Noninvasive Ventilation Vs. High-flow Nasal Oxygen on Intubation-free Survival in Acute Hypoxemic Respiratory Failure: the TRIPOD Randomized Clinical Trial","phase":"NA","overall_status":"RECRUITING","enrollment_count":1300,"lead_sponsor_name":"Southeast University, China","has_results":false},{"nct_id":"NCT07117318","title":"Rectal NSAIDs With/Without PD Stent for PEP Prevention","phase":"NA","overall_status":"RECRUITING","enrollment_count":1278,"lead_sponsor_name":"Air Force Military Medical University, China","has_results":false},{"nct_id":"NCT06727851","title":"ESGE-Quality Improvement in Endoscopy: ERCP","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1254,"lead_sponsor_name":"Universität Münster","has_results":false},{"nct_id":"NCT01864746","title":"A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1250,"lead_sponsor_name":"GBG Forschungs GmbH","has_results":true},{"nct_id":"NCT05947461","title":"Prevention of Post-ERCP Pancreatitis by Indomethacin vs Diclofenac","phase":"NA","overall_status":"TERMINATED","enrollment_count":1204,"lead_sponsor_name":"Air Force Military Medical University, China","has_results":false},{"nct_id":"NCT04509544","title":"Satisfaction and Preferences About Motor Rehabilitation in People With Cerebral Palsy: ESPaCe, a French Survey","phase":"","overall_status":"COMPLETED","enrollment_count":1159,"lead_sponsor_name":"Fondation Paralysie Cérébrale","has_results":false},{"nct_id":"NCT07247682","title":"Dose-escalation of Rectal Indomethacin for Preventing PEP","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":1036,"lead_sponsor_name":"The First Affiliated Hospital of Anhui Medical University","has_results":false},{"nct_id":"NCT06367322","title":"Statins and Post-ERCP Acute Pancreatitis (Stark Project)","phase":"","overall_status":"COMPLETED","enrollment_count":1016,"lead_sponsor_name":"Hospital General Universitario de Alicante","has_results":false},{"nct_id":"NCT07244432","title":"Post-ERCP Pancreatitis - Prophylactic Measures Implementation Study (PEP-PROMIS)","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Branislav Kuncak","has_results":false},{"nct_id":"NCT04062617","title":"Cmplications of ERCP","phase":"","overall_status":"COMPLETED","enrollment_count":929,"lead_sponsor_name":"Post Graduate Institute of Medical Education and Research, Chandigarh","has_results":false},{"nct_id":"NCT03137459","title":"STAMP: Sharing and Talking About My Preferences","phase":"NA","overall_status":"COMPLETED","enrollment_count":909,"lead_sponsor_name":"Yale University","has_results":true},{"nct_id":"NCT07329803","title":"Pre-cut Versus Intentional Double Guidewire for ERCP Cannulation: Prospective, Randomized Controlled Trial","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":840,"lead_sponsor_name":"Asian Institute of Gastroenterology, India","has_results":false},{"nct_id":"NCT04145336","title":"7 cm vs. 5 cm Pancreatic Stents for the Prevention of Post-ERCP Pancreatitis in High-risk Patients","phase":"NA","overall_status":"UNKNOWN","enrollment_count":800,"lead_sponsor_name":"Air Force Military Medical University, China","has_results":false},{"nct_id":"NCT07397416","title":"Impact of Implementing a Rapid PCR-based Algorithm for Carbapenemase-producing Enterobacterales (CPE) and Infection Control Bundle in a Tertiary Hospital","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":800,"lead_sponsor_name":"Hospital Italiano de Buenos Aires","has_results":false},{"nct_id":"NCT06250803","title":"Early Pancreatic Stent Placement for Preventing PEP","phase":"NA","overall_status":"RECRUITING","enrollment_count":768,"lead_sponsor_name":"The First Affiliated Hospital of Anhui Medical University","has_results":false},{"nct_id":"NCT02705677","title":"Biobanking of Rett Syndrome and Related Disorders","phase":"","overall_status":"COMPLETED","enrollment_count":752,"lead_sponsor_name":"University of Alabama at Birmingham","has_results":false},{"nct_id":"NCT04619511","title":"Risk Factors for Post-ESWL and Post-ERCP Pancreatitis","phase":"","overall_status":"COMPLETED","enrollment_count":714,"lead_sponsor_name":"Changhai Hospital","has_results":false},{"nct_id":"NCT05267379","title":"An European Multi-centre Cohort Study for Unravelling Pharmacokinetic and Genetic Factors Underlying Post-ERCP Pancreatitis","phase":"","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"Radboud University Medical Center","has_results":false},{"nct_id":"NCT05310409","title":"PAN-PROMISE to Detect Post-ERCP Pancreatitis Symptoms","phase":"","overall_status":"COMPLETED","enrollment_count":700,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT06095947","title":"Exploration on the Quadrivalent Influenza Vaccine Immunization Schedule for Children Aged 3-8 Years","phase":"","overall_status":"COMPLETED","enrollment_count":652,"lead_sponsor_name":"Hualan Biological Bacterin Co. Ltd.","has_results":false},{"nct_id":"NCT01743989","title":"A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":620,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03643900","title":"The Efficacy of Pancreatic Duct Stenting With Rectal Indomethacin in Preventing Post-ERCP Pancreatitis","phase":"NA","overall_status":"COMPLETED","enrollment_count":618,"lead_sponsor_name":"First People's Hospital of Hangzhou","has_results":false},{"nct_id":"NCT03771547","title":"ERCP in Super-aged Patients Considering Difficult Cannulation: Challenges and Adverse Events","phase":"","overall_status":"COMPLETED","enrollment_count":614,"lead_sponsor_name":"The Second Hospital of Nanjing Medical University","has_results":false},{"nct_id":"NCT06836830","title":"PEEP vs. ZEEP in Out-of-Hospital-Cardiac-Arrest","phase":"NA","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Muehlenkreiskliniken, MKK","has_results":false},{"nct_id":"NCT06848647","title":"Treatment of Sleep Apnea to Improve Metabolic Health","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Uppsala University","has_results":false},{"nct_id":"NCT06857539","title":"Assessing Intellectual and Motor Outcomes in High-risk Infants","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":600,"lead_sponsor_name":"University College Cork","has_results":false},{"nct_id":"NCT07292532","title":"Learning Cardiopulmonary Resuscitation in the School Setting: RCP-KNOW Project.","phase":"NA","overall_status":"RECRUITING","enrollment_count":550,"lead_sponsor_name":"University of Castilla-La Mancha","has_results":false},{"nct_id":"NCT06260878","title":"Short-term Intravenous Fluids for Prevention of Post-ERCP Pancreatitis","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":505,"lead_sponsor_name":"University of Calgary","has_results":false},{"nct_id":"NCT07173179","title":"Papillary Epinephrine Injection Combined With Rectal Indomethacin","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":504,"lead_sponsor_name":"Duzce University","has_results":false},{"nct_id":"NCT00499317","title":"Genetic Study of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Boston Children's Hospital","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}